tritton thomas (14 Ergebnisse)

Zustand: Good. This is an ex-library book and may have the usual library/used-book markings inside.This book has hardback covers. In good all round condition. Please note the Image in this listing is a stock photo and may not match the covers of the actual item,900grams, ISBN:0632034416.

Zustand: Fair. This is an ex-library book and may have the usual library/used-book markings inside.This book has hardback covers. In fair condition, suitable as a study copy. No dust jacket. Please note the Image in this listing is a stock photo and may not match the covers of the actual item,900grams, ISBN:9780632034413.

gebundene Ausgabe. Zustand: Gut. 288 Seiten; Das hier angebotene Buch stammt aus einer teilaufgelösten wissenschaftlichen Bibliothek und trägt die entsprechenden Kennzeichnungen (Rückenschild, Instituts-Stempel.); leichte altersbedingte Anbräunung des Papiers; der Buchzustand ist ansonsten ordentlich und dem Alter entsprechend gut. In ENGLISCHER Sprache. Sprache: Englisch Gewicht in Gramm: 560.

Paperback. Zustand: Good. No Jacket. Pages can have notes/highlighting. Spine may show signs of wear. ~ ThriftBooks: Read More, Spend Less.

Zustand: New. In.

Paperback. Zustand: Brand New. reprint edition. 299 pages. 9.25x6.10x0.70 inches. In Stock.

Zustand: New. Proceedings of the NATO Advanced Study Institute on Specific Approaches in Cancer Therapy: Differentiation, Immunomodulation and Angiogenesis held at Erice, Italy, October 17-27, 1992Provided here is a comprehensive examination of the basicand clinical .

Zustand: New. In.

Zustand: New. In.

Taschenbuch. Zustand: Neu. Neuware - Provided here is a comprehensive examination of the basicand clinical condition of three innovative and promisingapproaches to cancer therapy, which may support or evensubstitute chemotherapy: differentiation, immunomodulation,and inhibition of angiogenesis.Differentiation shouldnormalize neoplastic cells and makethem compatible with the host. Its feasibility withretinoids, interferons, chemotherapeutic and other agents isdiscussed. Modulation by biological agents, cytotoxiceffector cells and drugs is considered in attempts toboost endogenous antitumour defenses and/or to renderneoplastic cells more susceptible to the immune attack ofthe host. Finally, the important aspect of interfering withtumour blood vessel development and function is takeninto account.Consideringthe importance that chemotherapy has in cancertreatment and in view of a more and more integratedstrategy, the relationship between the aforementionedapproaches and chemotherapeutic agents and chemoresistanceis treated in detail.

Taschenbuch. Zustand: Neu. Organ Directed Toxicities of Anticancer Drugs | Proceedings of the First International Symposium on the Organ Directed Toxicities of the Anticancer Drugs Burlington, Vermont, USA-June 4-6, 1987 | Miles P. Hacker (u. a.) | Taschenbuch | xii | Englisch | 2011 | Humana | EAN 9781461292050 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.

Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - The addition of chemotherapy as an effective means to treat cancer has had a major impact on selected human malignancies. Due to a general inability to dif ferentiate between normal and neoplastic cells, little selectivity exists in currently used oncolytic drugs. Consequently, significant toxicity to the patient is expected when systemic cancer chemotherapy is chosen as an appropriate therapeutic in tervention. Much of this toxicity, such as damage to the bone marrow, gastroin testinal tract, or hair follicles, is predictable based upon the fact that anticancer drugs kill actively dividing cells. These types of toxicities, while serious, are usually manageable and reversible and are, therefore, not often considered to be dose limiting. Unfortunately, several of the most important anticancer drugs also damage tissues in which the growth fraction is relatively small. Such toxicities can not be predicted based on the chemical structure of the drugs, are often not detected in preclinical studies, and are encountered frequently for the first time in clinical studies. Further, unlike most of the proliferative-dependent toxicities, the unpre dicted toxicities are usually irreversible or only partially reversible upon cessation of drug administration. Because of this, the unpredicted toxicities are referred to as dose limiting. They represent a significant barrier to the ultimate efficacy of several of our most important anticancer drugs.

Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - The addition of chemotherapy as an effective means to treat cancer has had a major impact on selected human malignancies. Due to a general inability to dif ferentiate between normal and neoplastic cells, little selectivity exists in currently used oncolytic drugs. Consequently, significant toxicity to the patient is expected when systemic cancer chemotherapy is chosen as an appropriate therapeutic in tervention. Much of this toxicity, such as damage to the bone marrow, gastroin testinal tract, or hair follicles, is predictable based upon the fact that anticancer drugs kill actively dividing cells. These types of toxicities, while serious, are usually manageable and reversible and are, therefore, not often considered to be dose limiting. Unfortunately, several of the most important anticancer drugs also damage tissues in which the growth fraction is relatively small. Such toxicities can not be predicted based on the chemical structure of the drugs, are often not detected in preclinical studies, and are encountered frequently for the first time in clinical studies. Further, unlike most of the proliferative-dependent toxicities, the unpre dicted toxicities are usually irreversible or only partially reversible upon cessation of drug administration. Because of this, the unpredicted toxicities are referred to as dose limiting. They represent a significant barrier to the ultimate efficacy of several of our most important anticancer drugs.

Zustand: New. Proceedings of the First International Symposium on the Organ Directed Toxicities of Anticancer Drugs convened at Burlington, VT, June 4-6, 1987. Editor(s): Hacker, Miles P.; Lazo, John S.; Tritton, Thomas R. Series: Developments in Oncology. Num Pages: 254 pages, biography. BIC Classification: MJCL. Category: (P) Professional & Vocational; (UP) Postgraduate, Research & Scholarly. Dimension: 234 x 156 x 15. Weight in Grams: 559. . 1988. Hardback. . . . . Books ship from the US and Ireland.